Home> Products> gliclaglaze mr 30 consistent blood sugar control

{ "products": [ { "_id": "6661af452bed1f08484d625b", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "TRIGLICLAGLAZE 30 ", "description": "TRIGLICLAGLAZE 30 \nGliclazide (SR) Pioglitazone and Metformin HCL (SR)\nTRIGLICLAGLAZE 30 is a combination medication formulated to manage type 2 diabetes mellitus effectively. It combines three key components: Gliclazide (SR), Pioglitazone, and Metformin HCI (SR), each targeting different aspects of glucose regulation to achieve optimal blood sugar control.\n\nGliclazide (SR): Gliclazide is a sulfonylurea medication that works by stimulating the pancreas to release insulin, which helps lower blood sugar levels. The sustained-release (SR) formulation ensures a gradual and prolonged release of the medication, providing consistent glucose-lowering effects throughout the day.\n\nPioglitazone: Pioglitazone belongs to the thiazolidinedione class of drugs and enhances insulin sensitivity in muscle and fat tissues. By improving the body's response to insulin, Pioglitazone helps reduce insulin resistance and promotes better glucose utilization by cells.\n\nMetformin HCI (SR): Metformin is a biguanide medication that works primarily by reducing glucose production in the liver and increasing insulin sensitivity in peripheral tissues. The sustained-release formulation ensures a gradual release of Metformin, minimizing gastrointestinal side effects and providing extended blood sugar control.\n\nKey Benefits of TRIGLICLAGLAZE 30:\nComprehensive Glucose Control: The combination of Gliclazide (SR), Pioglitazone, and Metformin HCI (SR) targets multiple pathways involved in glucose metabolism. This comprehensive approach helps achieve better overall blood sugar control throughout the day.\n\nStimulates Insulin Release: Gliclazide stimulates insulin secretion from the pancreas, especially after meals, which is crucial for managing postprandial (after-meal) glucose spikes.\n\nImproves Insulin Sensitivity: Pioglitazone enhances insulin sensitivity in muscle and fat tissues, allowing for better glucose uptake and utilization by cells. This action helps reduce insulin resistance, a hallmark of type 2 diabetes.\n\nReduces Hepatic Glucose Production: Metformin HCI (SR) reduces the production of glucose in the liver, helping to lower fasting blood sugar levels and prevent excessive glucose release into the bloodstream.\n\nExtended Blood Sugar Control: The sustained-release formulations of Gliclazide and Metformin ensure a gradual and prolonged release of the medications, leading to consistent blood sugar control and minimizing the risk of hypoglycemia (low blood sugar) or hyperglycemia (high blood sugar) fluctuations.\n\nDosage and Administration:\nTRIGLICLAGLAZE 30 is typically taken orally once or twice daily, as prescribed by a healthcare provider.\nThe medication is often taken with meals to reduce the risk of gastrointestinal side effects.\nDosage adjustments may be necessary based on blood sugar levels and individual response to treatment. Follow your doctor's instructions carefully.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/trigliclaglaze-30-134278", "price": 125.0, "discountamount": 37.5, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "day", "body", "risk", "drugs", "meals", "Order", "liver", "cells", "EMAIL", "doctor", "muscle", "action", "pancreas", "hallmark", "treatment", "Gliclazide", "fat tissues", "information", "medications", "bloodstream", "Pioglitazone", "sterisonline", "postprandial", "hypoglycemia", "fluctuations", "instructions", "sterispharma", "Key Benefits", "hyperglycemia", "CALL/WHATSAPP", "Metformin HCL", "Metformin HCI", "glucose uptake", "Administration", "TRIGLICLAGLAZE", "low blood sugar", "gradual release", "Insulin Release", "high blood sugar", "prolonged release", "insulin secretion", "different aspects", "multiple pathways", "peripheral tissues", "insulin resistance", "Dosage adjustments", "blood sugar levels", "glucose metabolism", "glucose regulation", "glucose utilization", "individual response", "insulin sensitivity", "healthcare provider", "meal) glucose spikes", "three key components", "biguanide medication", "combination medication", "comprehensive approach", "thiazolidinedione class", "sulfonylurea medication", "type 2 diabetes mellitus", "excessive glucose release", "Hepatic Glucose Production", "overall blood sugar control", "optimal blood sugar control", "extended blood sugar control", "gastrointestinal side effects", "sustained-release formulation", "Comprehensive Glucose Control", "consistent blood sugar control", "sustained-release (SR) formulation", "consistent glucose-lowering effects" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1484, "imageuri": "https://productimages.withfloats.com/actual/6661af49f21358d53af3ccec.png", "tileimageuri": "https://productimages.withfloats.com/tile/6661af49f21358d53af3ccec.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-06T12:44:53.071Z", "updatedon": "2024-06-28T12:15:14.626Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/trigliclaglaze-30-/1484", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "TRIGLICLAGLAZE 30 ", "category": "DIABETIC RANGE", "tags": [ "TRIGLICLAGLAZE 30", "Gliclazide (SR)", "Pioglitazone", "Metformin HCL (SR)", "Metformin SR 500mg uses", "Metformin hydrochloride 500 mg", "Metformin SR 500 side effects" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "665ef7cfea22b014e8aefff9", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "GLICLAGLAZE MR 30 ", "description": "GLICLAGLAZE MR 30 \ngliclazide sr (30 mg)\nIntroduction\nGLICLAGLAZE MR 30 is specifically formulated for individuals managing Type 2 diabetes. This medication utilizes a sustained release (SR) form of Gliclazide at a 30 mg dosage, focusing on providing a steady, controlled release of the drug to maintain optimal blood sugar levels throughout the day.\n\nHow It Works\n\nGliclazide SR (30 mg): Gliclazide is a sulfonylurea class drug that increases insulin secretion from the pancreas. Unlike standard formulations, the SR version releases the medication gradually, which helps to stabilize blood sugar levels and reduces the risk of severe fluctuations that can lead to hypoglycemia. This mechanism not only enhances the body’s natural insulin use but also supports overall vascular health, decreasing the risk of complications associated with diabetes, such as cardiovascular disease.\nBenefits\nGLICLAGLAZE MR 30 is an excellent choice for patients who require a mild enhancement in their insulin secretion with a lower risk of hypoglycemia. The SR formulation provides a more predictable pharmacokinetic profile, which is crucial for maintaining a stable glycemic control. This can significantly improve the quality of life for patients by reducing common side effects associated with blood sugar spikes and drops.\n\nDosage and Administration\n\nDosage: The dose of GLICLAGLAZE MR 30 should be adjusted based on the patient’s blood glucose response and previous treatment history. Regular monitoring of blood glucose and glycated hemoglobin (HbA1c) levels is recommended to ensure that the dosage is effective.\nAdministration: This medication should be taken with breakfast or the first main meal of the day. The tablet should be swallowed whole to maintain the integrity of the sustained release mechanism.\nSide Effects\nPossible side effects of GLICLAGLAZE MR 30 include gastrointestinal issues such as nausea and upset stomach. Due to its sulfonylurea component, there is a risk of hypoglycemia, although it is generally lower compared to other sulfonylureas due to the sustained release formulation.\n\nConclusion\nGLICLAGLAZE MR 30 is a practical and effective solution for managing Type 2 diabetes, especially suited for patients seeking a gentle modification in their diabetes treatment plan with sustained drug release. It simplifies diabetes management, potentially enhancing adherence and minimizing the risk of dosage-related complications. As with any medication, consultation with a healthcare provider is essential to tailor the treatment to individual needs and conditions.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/gliclaglaze-mr-30-133422", "price": 83.0, "discountamount": 24.9, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "day", "dose", "life", "body", "drops", "EMAIL", "Order", "upset", "tablet", "nausea", "stomach", "quality", "SR) form", "patients", "Benefits", "pancreas", "adherence", "integrity", "breakfast", "practical", "lower risk", "SR version", "medication", "conditions", "Conclusion", "individuals", "information", "sterisonline", "Introduction", "30 mg dosage", "consultation", "sterispharma", "hypoglycemia", "CALL/WHATSAPP", "Gliclazide SR", "HbA1c) levels", "SR formulation", "GLICLAGLAZE MR", "first main meal", "Type 2 diabetes", "mild enhancement", "individual needs", "excellent choice", "insulin secretion", "effective solution", "Regular monitoring", "blood sugar spikes", "healthcare provider", "diabetes management", "gentle modification", "other sulfonylureas", "common side effects", "glycated hemoglobin", "severe fluctuations", "natural insulin use", "Possible side effects", "standard formulations", "Administration Dosage", "sulfonylurea component", "sustained drug release", "blood glucose response", "cardiovascular disease", "diabetes treatment plan", "stable glycemic control", "gastrointestinal issues", "overall vascular health", "sulfonylurea class drug", "steady, controlled release", "optimal blood sugar levels", "previous treatment history", "sustained release mechanism", "dosage-related complications", "sustained release formulation", "predictable pharmacokinetic profile" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1291, "imageuri": "https://productimages.withfloats.com/actual/665ef7d253245b8b6b459895.png", "tileimageuri": "https://productimages.withfloats.com/tile/665ef7d253245b8b6b459895.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-04T11:17:35.736Z", "updatedon": "2024-06-04T11:17:35.736Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/gliclaglaze-mr-30-/1291", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "GLICLAGLAZE MR 30 ", "category": "DIABETIC RANGE", "tags": null, "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "666c0efb162db0236048ba8c", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "VALPOTREAT CR 300 ", "description": "VALPOTREAT CR 300 \nSodium Valproate CR 300 mg\nIntroduction:\n\nVALPOTREAT CR 300 contains Sodium Valproate, a highly effective anticonvulsant and mood stabilizer, in a controlled-release (CR) formulation. With a dosage strength of 300mg, VALPOTREAT CR 300 is designed to provide sustained therapeutic effects for managing epilepsy and bipolar disorder, significantly enhancing the quality of life for patients.\nKey Features and Benefits:\n\nAnticonvulsant Action:\n\nVALPOTREAT CR 300 is highly effective in treating various types of seizures, including generalized tonic-clonic seizures, absence seizures, and complex partial seizures. It increases gamma-aminobutyric acid (GABA) levels in the brain, helping stabilize neuronal activity and prevent seizure episodes.\nMood Stabilization:\n\nSodium Valproate is also used as a mood stabilizer for treating bipolar disorder. It helps control manic episodes and provides mood stability, reducing the frequency and severity of mood swings.\nControlled-Release Formulation:\n\nThe controlled-release formulation of VALPOTREAT CR 300 ensures a steady release of the medication over time, maintaining consistent blood levels and reducing the need for frequent dosing. This leads to better symptom control and improved adherence to the treatment regimen.\nWell-Tolerated and Safe:\n\nVALPOTREAT CR 300 is generally well-tolerated with a favorable safety profile, making it a reliable option for long-term management of epilepsy and bipolar disorder.\nDosage and Administration:\n\nInitial Dosage for Epilepsy:\n\nThe initial dose of VALPOTREAT CR 300 for adults typically starts at 300-600mg per day, divided into two doses. The dose can be gradually increased based on the patient's response and tolerability, with a usual maintenance dose ranging from 1000-2000mg per day.\nInitial Dosage for Bipolar Disorder:\n\nFor the treatment of bipolar disorder, the initial dose usually starts at 300-600mg per day, divided into two doses. The dose can be gradually increased based on clinical response, with a typical maintenance dose ranging from 1000-1500mg per day.\nAdministration Instructions:\n\nVALPOTREAT CR 300 tablets should be taken orally with water. They can be taken with or without food, although taking them with food may help reduce gastrointestinal discomfort.\nContinued Monitoring:\n\nRegular monitoring of blood levels, liver function, and overall health is essential during VALPOTREAT CR 300 therapy to ensure therapeutic efficacy and patient safety.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order NOW\nhttps://www.sterisonline.com/product/valpotreat-cr-300-134219", "price": 78.0, "discountamount": 23.4, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "mg", "day", "life", "time", "food", "need", "EMAIL", "brain", "water", "adults", "option", "quality", "patients", "Benefits", "severity", "epilepsy", "adherence", "two doses", "frequency", "medication", "information", "mood swings", "Introduction", "initial dose", "sterisonline", "sterispharma", "tolerability", "GABA) levels", "Key Features", "various types", "CALL/WHATSAPP", "overall health", "Initial Dosage", "patient safety", "mood stability", "manic episodes", "steady release", "liver function", "mood stabilizer", "dosage strength", "symptom control", "frequent dosing", "bipolar disorder", "absence seizures", "seizure episodes", "neuronal activity", "treatment regimen", "clinical response", "Regular monitoring", "Mood Stabilization", "Sodium Valproate CR", "long-term management", "therapeutic efficacy", "Continued Monitoring", "Anticonvulsant Action", "usual maintenance dose", "gamma-aminobutyric acid", "consistent blood levels", "effective anticonvulsant", "complex partial seizures", "typical maintenance dose", "favorable safety profile", "VALPOTREAT CR 300 therapy", "VALPOTREAT CR 300 tablets", "Administration Instructions", "gastrointestinal discomfort", "sustained therapeutic effects", "Controlled-Release Formulation", "generalized tonic-clonic seizures" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1908, "imageuri": "https://productimages.withfloats.com/actual/666c0efef068be46bdec91c1.png", "tileimageuri": "https://productimages.withfloats.com/tile/666c0efef068be46bdec91c1.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-14T09:35:55.629Z", "updatedon": "2024-06-29T12:22:31.565Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/valpotreat-cr-300-/1908", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "VALPOTREAT CR 300 ", "category": "NEUROLOGY RANGE", "tags": [ "Sodium Valproate CR 300 mg", "VALPOTREAT CR 300", "", "VALPOTREAT CR 300", "valprol cr 300 side effects", "valprol cr 300 generic name", "valprol cr 300 dosage" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6661afd366170d1ff8cb4626", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "TRIGLICLAGLAZE 60 ", "description": "TRIGLICLAGLAZE 60 \nGliclazide 60mg (SR) Pioglitazone 15mg and Metformin HCL 500mg(SR)\nTRIGLICLAGLAZE 60 is a combination medication designed to effectively manage type 2 diabetes mellitus by addressing multiple aspects of glucose regulation. It combines three key components: Gliclazide 60mg (SR), Pioglitazone 15mg, and Metformin HCI 500mg (SR), each contributing to improved blood sugar control through distinct mechanisms of action.\n\nGliclazide 60mg (SR): Gliclazide is a sulfonylurea medication that stimulates the pancreas to release insulin. This insulin release helps lower blood sugar levels, especially after meals, by facilitating glucose uptake into cells.\n\nPioglitazone 15mg: Pioglitazone belongs to the thiazolidinedione class and works by improving insulin sensitivity in peripheral tissues such as muscle and fat cells. Enhanced insulin sensitivity allows for better utilization of glucose, reducing insulin resistance and promoting more efficient blood sugar management.\n\nMetformin HCI 500mg (SR): Metformin is a biguanide medication that primarily works by reducing glucose production in the liver and increasing insulin sensitivity in muscle cells. It also improves glucose uptake by cells and reduces the absorption of glucose from the digestive tract.\n\nKey Benefits of TRIGLICLAGLAZE 60:\nComprehensive Glucose Control: By combining Gliclazide (SR), Pioglitazone, and Metformin HCI (SR), TRIGLICLAGLAZE 60 offers comprehensive control over blood sugar levels throughout the day.\n\nStimulates Insulin Release: Gliclazide's action in stimulating insulin release from the pancreas helps manage postprandial (after-meal) glucose spikes, contributing to overall glucose control.\n\nImproves Insulin Sensitivity: Pioglitazone enhances insulin sensitivity in tissues, leading to better glucose uptake and utilization by cells. This helps reduce insulin resistance, a common feature of type 2 diabetes.\n\nReduces Glucose Production: Metformin HCI lowers glucose production in the liver and improves insulin action in muscle cells, leading to lower fasting blood sugar levels and enhanced glucose utilization.\n\nExtended Release Formulation: The sustained-release formulations of Gliclazide and Metformin ensure a gradual and prolonged release of the medications, providing consistent blood sugar control and minimizing the risk of hypoglycemia or hyperglycemia.\n\nDosage and Administration:\nTRIGLICLAGLAZE 60 is typically taken orally once or twice daily, with meals to reduce gastrointestinal side effects.\nDosage adjustments may be required based on blood sugar levels and individual response to treatment. Follow your healthcare provider's instructions.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/trigliclaglaze-60-134279", "price": 155.0, "discountamount": 47.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "SR", "day", "risk", "meals", "Order", "liver", "EMAIL", "gradual", "fasting", "pancreas", "Enhanced", "treatment", "fat cells", "absorption", "information", "medications", "muscle cells", "Pioglitazone", "sterisonline", "Key Benefits", "hypoglycemia", "instructions", "sterispharma", "postprandial", "hyperglycemia", "CALL/WHATSAPP", "Metformin HCL", "Metformin HCI", "Administration", "glucose uptake", "TRIGLICLAGLAZE", "common feature", "glucose spikes", "insulin action", "insulin release", "Gliclazide 60mg", "digestive tract", "multiple aspects", "prolonged release", "Dosage adjustments", "peripheral tissues", "blood sugar levels", "glucose production", "insulin resistance", "glucose regulation", "distinct mechanisms", "healthcare provider", "individual response", "glucose utilization", "insulin sensitivity", "three key components", "biguanide medication", "comprehensive control", "combination medication", "sulfonylurea medication", "thiazolidinedione class", "overall glucose control", "type 2 diabetes mellitus", "Extended Release Formulation", "Comprehensive Glucose Control", "gastrointestinal side effects", "sustained-release formulations", "consistent blood sugar control", "efficient blood sugar management" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1485, "imageuri": "https://productimages.withfloats.com/actual/6661afd7f21358d53af3cd71.png", "tileimageuri": "https://productimages.withfloats.com/tile/6661afd7f21358d53af3cd71.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-06T12:47:15.16Z", "updatedon": "2024-06-28T12:12:27Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//trigliclaglaze-60-/1485", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "TRIGLICLAGLAZE 60 ", "category": "DIABETIC RANGE", "tags": [ "TRIGLICLAGLAZE 60", "Gliclazide 60mg (SR)", "Pioglitazone 15mg", "Metformin HCL 500mg(SR)", "Metformin SR 500mg uses", "Metformin SR 500 price", "Metformin SR 500 side effects" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "66615f8cccd5ce1a10758f47", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "PIOSTERIS 30 ", "description": "PIOSTERIS 30 \nPioglitazone (30mg)\nIntroduction to PIOSTERIS 30\nPIOSTERIS 30 contains Pioglitazone 30mg, a medication used primarily for the management of type 2 diabetes mellitus. Pioglitazone belongs to a class of drugs known as thiazolidinediones (TZDs), which help improve blood sugar control by increasing the body's sensitivity to insulin. This medication is typically used in combination with diet and exercise to enhance glycemic control in adults with type 2 diabetes.\n\nWhat is Pioglitazone?\nOverview of Pioglitazone\nPioglitazone is an oral diabetes medicine that works by making cells more sensitive to insulin, thereby allowing the body to use insulin more effectively. This helps lower blood sugar levels in patients with type 2 diabetes. Pioglitazone can be used alone or in combination with other antidiabetic medications.\n\nMechanism of Action\nInsulin Sensitization: Pioglitazone works by activating peroxisome proliferator-activated receptor gamma (PPARγ) receptors, which are involved in the regulation of genes responsible for glucose and lipid metabolism. This activation increases the sensitivity of body tissues to insulin.\nGlucose Uptake: By improving insulin sensitivity, Pioglitazone enhances glucose uptake in muscle and adipose tissue and reduces hepatic glucose production, leading to lower blood sugar levels.\nBenefits of PIOSTERIS 30\nEffective Blood Sugar Management\nImproved Insulin Sensitivity: PIOSTERIS 30 helps improve the body's response to insulin, leading to better control of blood sugar levels.\nComprehensive Glycemic Control: By targeting insulin resistance, Pioglitazone provides a unique mechanism of action that complements other diabetes medications, offering comprehensive blood sugar management.\nSupport for Diabetes Management\nDiet and Exercise Adjunct: PIOSTERIS 30 is an excellent adjunct to diet and exercise, helping patients achieve better blood sugar control when lifestyle modifications alone are insufficient.\nReduced Risk of Complications: By maintaining more stable blood sugar levels, PIOSTERIS 30 can help reduce the risk of long-term complications associated with diabetes, such as cardiovascular disease, neuropathy, and retinopathy.\nAdditional Health Benefits\nLipid Profile Improvement: Pioglitazone has been shown to improve lipid profiles by lowering triglycerides and increasing HDL cholesterol levels, which can provide additional cardiovascular benefits.\nHow to Use PIOSTERIS 30\nDosage and Administration\nRecommended Dosage: The typical dosage of PIOSTERIS 30 is one tablet taken once daily. Your healthcare provider may adjust the dosage based on your individual response and blood sugar levels.\nAdministration: Take the tablet with or without food. Swallow the tablet whole with a full glass of water. Consistency is key, so take the medication at the same time each day.\nGuidelines for Optimal Use\nConsistent Use: For best results, take PIOSTERIS 30 regularly as prescribed by your healthcare provider.\nMonitor Blood Sugar Levels: Regularly check your blood sugar levels to ensure the medication is effectively controlling your diabetes. Adjustments to your treatment plan may be necessary based on these readings.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/piosteris-30-134190", "price": 95.0, "discountamount": 28.5, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "TZDs", "diet", "food", "cells", "genes", "water", "Order", "class", "EMAIL", "drugs", "muscle", "adults", "Action", "Support", "readings", "Overview", "patients", "same time", "PIOSTERIS", "full glass", "Guidelines", "neuropathy", "one tablet", "activation", "regulation", "Optimal Use", "combination", "information", "Adjustments", "Consistency", "retinopathy", "sterisonline", "sterispharma", "best results", "Introduction", "Reduced Risk", "body tissues", "CALL/WHATSAPP", "triglycerides", "Administration", "typical dosage", "lipid profiles", "treatment plan", "Consistent Use", "Glucose Uptake", "adipose tissue", "Exercise Adjunct", "PPARγ) receptors", "unique mechanism", "lipid metabolism", "excellent adjunct", "Pioglitazone 30mg", "insulin resistance", "thiazolidinediones", "Recommended Dosage", "insulin sensitivity", "healthcare provider", "Diabetes Management", "individual response", "blood sugar control", "Insulin Sensitization", "cardiovascular disease", "HDL cholesterol levels", "oral diabetes medicine", "lifestyle modifications", "long-term complications", "type 2 diabetes mellitus", "lower blood sugar levels", "stable blood sugar levels", "Lipid Profile Improvement", "other diabetes medications", "Additional Health Benefits", "hepatic glucose production", "Comprehensive Glycemic Control", "other antidiabetic medications", "Effective Blood Sugar Management", "additional cardiovascular benefits", "comprehensive blood sugar management", "peroxisome proliferator-activated receptor gamma" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1407, "imageuri": "https://productimages.withfloats.com/actual/66615f8f8e77bb2c715607af.png", "tileimageuri": "https://productimages.withfloats.com/tile/66615f8f8e77bb2c715607af.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-06T07:04:44.526Z", "updatedon": "2024-06-29T10:30:40.061Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//piosteris-30-/1407", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "PIOSTERIS 30 ", "category": "DIABETIC RANGE", "tags": [ "PIOSTERIS 30", "Pioglitazone (30mg)", "Pioglitazone 30mg uses", "Pioglitazone 30mg side effects", "Pioglitazone dose", "pioglitazone price" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "665ef948161afa2274ff25b9", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "GLICLAGALZE MR 60 ", "description": "GLICLAGALZE MR 60 \nGliclazide SR 60 mg\nIntroduction\nGLICLAGALZE MR 60 is an oral medication tailored for the treatment of Type 2 diabetes, featuring a 60 mg dose of Gliclazide in a sustained release (SR) formulation. This medication is designed to offer consistent control of blood sugar levels throughout the day, minimizing fluctuations and improving overall diabetes management.\n\nMechanism of Action\n\nGliclazide SR (60 mg): Gliclazide is a member of the sulfonylurea class of diabetes medications. It operates by stimulating the pancreatic beta cells to produce more insulin, a key hormone that helps lower blood glucose. The SR formulation allows for a gradual release of Gliclazide, maintaining a steady level of the drug in the bloodstream, which helps to prevent the peaks and troughs in blood sugar levels that can be problematic in diabetes management.\nBenefits\nGLICLAGALZE MR 60 is particularly beneficial for patients who need a moderate increase in their insulin production but are concerned about the risks of hypoglycemia associated with other diabetes treatments. The sustained release formulation ensures a more uniform effect over the day, which can lead to better adherence to treatment and overall patient satisfaction.\n\nDosage and Administration\n\nDosage: The dosage should be individualized based on the patient’s current treatment regimen, effectiveness, and tolerability. It is crucial to monitor blood glucose levels regularly to ensure optimal control and to adjust the dosage as needed.\nAdministration: This medication should be taken with food, ideally with the first main meal of the day. The tablet must be swallowed whole to maintain the integrity of the sustained release mechanism and ensure effective drug delivery.\nSide Effects\nCommon side effects of GLICLAGALZE MR 60 may include gastrointestinal disturbances such as nausea and upset stomach. There is also a risk of hypoglycemia, particularly if meals are skipped or delayed, or when combined with other glucose-lowering medications.\n\nConclusion\nGLICLAGALZE MR 60 offers a reliable and effective approach for managing Type 2 diabetes, providing a balanced and prolonged action to stabilize blood glucose levels. It supports a comprehensive diabetes management plan, which should include regular physical activity, diet modification, and routine monitoring of blood glucose. As with any medication regimen, it is important to consult with a healthcare provider to adjust the treatment according to individual health needs and response to therapy.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/gliclagalze-mr-60-133418\n\n\n\n\n\n", "price": 128.0, "discountamount": 38.4, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "day", "food", "peaks", "risks", "upset", "meals", "Order", "EMAIL", "member", "nausea", "tablet", "stomach", "therapy", "troughs", "reliable", "response", "balanced", "Benefits", "patients", "integrity", "adherence", "60 mg dose", "Conclusion", "key hormone", "bloodstream", "information", "tolerability", "Introduction", "fluctuations", "sterispharma", "hypoglycemia", "sterisonline", "steady level", "effectiveness", "Gliclazide SR", "CALL/WHATSAPP", "uniform effect", "GLICLAGALZE MR", "SR formulation", "gradual release", "optimal control", "Type 2 diabetes", "oral medication", "first main meal", "prolonged action", "diet modification", "moderate increase", "blood sugar levels", "sulfonylurea class", "consistent control", "effective approach", "insulin production", "routine monitoring", "medication regimen", "Common side effects", "healthcare provider", "blood glucose levels", "diabetes medications", "pancreatic beta cells", "Administration Dosage", "effective drug delivery", "individual health needs", "current treatment regimen", "other diabetes treatments", "regular physical activity", "overall diabetes management", "sustained release mechanism", "overall patient satisfaction", "sustained release formulation", "gastrointestinal disturbances", "other glucose-lowering medications", "comprehensive diabetes management plan" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1293, "imageuri": "https://productimages.withfloats.com/actual/665ef94b480b81124f8647ec.jpg", "tileimageuri": "https://productimages.withfloats.com/tile/665ef94b480b81124f8647ec.jpg", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-04T11:23:52.299Z", "updatedon": "2024-06-04T11:23:52.299Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/gliclagalze-mr-60-/1293", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "GLICLAGALZE MR 60 ", "category": "DIABETIC RANGE", "tags": null, "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "665ef6a3161afa2274ff2581", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "GLICLAGLAZE MET ", "description": "GLICLAGLAZE MET \ngliclazide SR (60mg),Metformin SR (500 mg)\nIntroduction\nGLICLAGLAZE MET is an advanced formulation designed for the effective management of Type 2 diabetes. This oral medication combines sustained release (SR) forms of Gliclazide (60 mg) and Metformin (500 mg), offering controlled and consistent blood glucose control throughout the day.\n\nMechanism of Action\n\nGliclazide SR (60 mg): As a sulfonylurea drug, Gliclazide SR works by stimulating insulin secretion from the beta cells of the pancreas. The sustained release form provides a gradual increase in insulin levels, reducing the risk of sudden drops in blood sugar that can lead to hypoglycemia.\nMetformin SR (500 mg): Metformin SR decreases hepatic glucose production and increases insulin sensitivity in peripheral tissues, notably muscles. Its sustained release formulation ensures a steady effect on blood sugar levels, improving metabolic response without the peaks and troughs associated with immediate-release forms.\nBenefits\nGLICLAGLAZE MET is specifically tailored to provide a more stable and prolonged effect in controlling blood sugar, which can enhance patient compliance and comfort. The combination of Gliclazide SR and Metformin SR in one tablet simplifies the treatment regimen, potentially improving adherence and reducing the risk of missed doses.\n\nDosage and Administration\n\nDosage: The dosage of GLICLAGLAZE MET should be individualized based on the patient's current control and therapeutic response. It is crucial to monitor blood glucose regularly to adjust the dosage appropriately.\nAdministration: This medication should be taken with meals to minimize gastrointestinal side effects and improve the absorption of the drug.\nSide Effects\nWhile GLICLAGLAZE MET is generally well tolerated, some patients may experience side effects such as gastrointestinal discomfort, including nausea and diarrhea. The risk of hypoglycemia is present but is generally lower with the sustained release formulation.\n\nConclusion\nGLICLAGLAZE MET offers a balanced and effective approach to managing Type 2 diabetes by combining two proven diabetes medications in a sustained release form. This regimen not only aids in maintaining steady blood glucose levels but also supports overall diabetes management by enhancing patient adherence to treatment. Patients are encouraged to maintain a dialogue with their healthcare provider to optimize treatment outcomes and address any concerns during their treatment journey.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/gliclaglaze-met-133421\n\n\n\n\n\n", "price": 149.0, "discountamount": 44.7, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "mg", "day", "risk", "Order", "EMAIL", "peaks", "doses", "meals", "stable", "Action", "nausea", "muscles", "troughs", "Benefits", "pancreas", "diarrhea", "balanced", "dialogue", "concerns", "patients", "SR) forms", "Mechanism", "beta cells", "Conclusion", "one tablet", "controlled", "absorption", "combination", "information", "Metformin SR", "sudden drops", "hypoglycemia", "Introduction", "sterispharma", "sterisonline", "steady effect", "CALL/WHATSAPP", "gliclazide SR", "insulin levels", "oral medication", "current control", "Type 2 diabetes", "GLICLAGLAZE MET", "gradual increase", "prolonged effect", "insulin secretion", "patient adherence", "treatment journey", "treatment regimen", "sulfonylurea drug", "effective approach", "blood sugar levels", "metabolic response", "peripheral tissues", "patient compliance", "treatment outcomes", "healthcare provider", "insulin sensitivity", "advanced formulation", "effective management", "therapeutic response", "Administration Dosage", "sustained release form", "immediate-release forms", "hepatic glucose production", "overall diabetes management", "steady blood glucose levels", "gastrointestinal discomfort", "gastrointestinal side effects", "two proven diabetes medications", "consistent blood glucose control" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1289, "imageuri": "https://productimages.withfloats.com/actual/665ef6a67b1fc3f9dd48259d.png", "tileimageuri": "https://productimages.withfloats.com/tile/665ef6a67b1fc3f9dd48259d.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-04T11:12:35.652Z", "updatedon": "2024-06-04T11:12:35.652Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//gliclaglaze-met-/1289", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "GLICLAGLAZE MET ", "category": "DIABETIC RANGE", "tags": null, "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "68c29ba02244c906e7790e2b", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "TELAVINCE 300", "description": "TELAVINCE 300 is a high-quality antiviral medication containing Tenofovir Disoproxil Fumarate 300 mg, specifically formulated for the effective management of HIV-1 infection and chronic Hepatitis B in adults and adolescents. Manufactured under strict pharmaceutical standards, TELAVINCE 300 offers consistent, potent, and clinically proven antiviral action, helping to suppress viral replication and improve immune function.\n\nTenofovir Disoproxil Fumarate is a nucleotide reverse transcriptase inhibitor (NtRTI). It works by interfering with the enzyme reverse transcriptase, which is essential for viral replication in HIV and Hepatitis B viruses. By inhibiting this enzyme, TELAVINCE 300 reduces the amount of virus in the body, helping to prevent further immune system damage and liver complications.\n\n \nKey Indications:\n \n\nTELAVINCE 300 is indicated for:\n\nHIV-1 Infection: In combination with other antiretroviral agents for the treatment of HIV-1 in adults and adolescents (aged 12 years and older, weighing at least 35 kg).\n\nChronic Hepatitis B: For the treatment of chronic hepatitis B virus infection in adults and adolescents with compensated liver disease and evidence of active viral replication.\n\n \nMechanism of Action:\n \nTenofovir Disoproxil Fumarate is a prodrug of tenofovir, which, once absorbed and metabolized in the body, is converted into tenofovir diphosphate, the active form. Tenofovir diphosphate acts as a competitive inhibitor of reverse transcriptase, incorporating itself into the viral DNA chain and causing premature chain termination. This process disrupts the life cycle of the virus, significantly reducing its ability to multiply and spread.\n\n \nDosage and Administration:\n \n\nRecommended Dose for Adults and Adolescents (≥12 years, ≥35 kg): One tablet (300 mg) once daily, preferably with food.\n\nFor HIV Treatment: Administer in combination with other antiretroviral medications as per the treatment regimen.\n\nFor Chronic Hepatitis B: Monotherapy or as part of combination therapy, depending on patient condition and physician's assessment.\n\nDosage adjustments may be required in patients with renal impairment. Close monitoring is recommended for patients with existing kidney disease.\n\n \nKey Benefits of TELAVINCE 300:\n \n\nPotent Antiviral Action: Rapid and sustained suppression of HIV and HBV replication.\nOnce-Daily Dosing: Improves patient compliance and treatment adherence.\n\nBacked by Clinical Research: Proven efficacy in managing viral load and improving immune markers (CD4 count).\n\nTrusted Quality: Manufactured under GMP-certified facilities with stringent quality control processes.\n\nPart of First-Line Therapy: Recommended in various national and international treatment guidelines for HIV and Hepatitis B.\n\n \nSafety and Precautions:\n \n\nRenal Monitoring: Tenofovir may affect kidney function. Routine renal function tests are recommended before and during treatment.\n\nBone Mineral Density: Long-term use may reduce bone mineral density. Consider monitoring in patients at risk of osteopenia or osteoporosis.\n\nHepatic Flare: Discontinuation of therapy in hepatitis B patients may result in severe acute exacerbations. Liver function should be closely monitored post-treatment.\n\nLactic Acidosis and Hepatomegaly: Rare but serious side effects. Patients presenting symptoms such as abdominal pain, fatigue, or difficulty breathing should seek immediate medical attention.\n\n \n\nPossible Side Effects:\n \n\nMost patients tolerate TELAVINCE 300 well. However, some may experience:\n\nNausea\n\nDiarrhea\n\nHeadache\n\nFatigue\n\nRash\n\nDizziness\n\nDecreased bone mineral density\n\nRenal impairment (in rare cases)\n\nIf any side effects persist or worsen, consult a healthcare professional immediately.\n\n \nStorage Instructions:\n \n\nStore in a cool, dry place below 30°C.\n\nProtect from light and moisture.\n\nKeep out of reach of children.\n\n \n\nWhy Choose TELAVINCE 300?\n \n\nTELAVINCE 300 offers a dependable, clinically validated solution for the long-term management of HIV and Hepatitis B. With its once-daily dosing and proven effectiveness, TELAVINCE 300 is an ideal choice for patients and healthcare providers looking for quality, safety, and therapeutic reliability. It is manufactured by a trusted name in healthcare, ensuring every tablet meets global pharmaceutical standards.\n\n \nDisclaimer:\n \n\nThis product description is for informational purposes only and is not a substitute for professional medical advice. Always consult your doctor or healthcare provider before starting any medication.", "price": 1480.0, "discountamount": 444.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2179, "imageuri": "https://productimages.withfloats.com/actual/68c29ba3794abb27ab248d73.png", "tileimageuri": "https://productimages.withfloats.com/tile/68c29ba3794abb27ab248d73.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-09-11T09:51:28.508Z", "updatedon": "2025-09-11T09:51:28.508Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/telavince-300/2179", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "Tenofovir Disoproxil Fumarate Tablets ip 300 mg", "category": "GENERAL RANGE", "tags": [], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "68b02393f5434d48fca8b8ca", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "TRELAQWK 50", "description": "TRELAQWK 50 is a modern oral antidiabetic tablet containing Trelagliptin 50 mg, specially developed for adults with type 2 diabetes mellitus. This once-weekly medication helps regulate blood sugar effectively, offering both convenience and strong clinical outcomes. With its advanced formulation, TRELAQWK 50 supports better glycemic control, making it easier for patients to lead a balanced and healthier lifestyle.\nManufactured under strict quality standards, TRELAQWK 50 ensures patient compliance, long-term safety, and efficacy in diabetes management.\nKey Ingredient\nTrelagliptin (50 mg):\nA unique, long-acting DPP-4 (dipeptidyl peptidase-4) inhibitor that allows weekly dosing, ensuring higher treatment adherence while maintaining effective control over blood glucose levels.\nKey Benefits of TRELAQWK 50\nProvides consistent blood sugar management with just one tablet per week\nEnhances insulin secretion while lowering glucagon levels in a glucose-dependent manner\nHelps reduce both fasting and postprandial blood glucose\nConvenient choice for patients with busy schedules who struggle with daily tablets\nLow risk of hypoglycemia when used as monotherapy\nSupports long-term improvement in HbA1c levels\nMechanism of Action – How TRELAQWK 50 Works\nTRELAQWK 50 works by blocking the DPP-4 enzyme, which normally degrades incretin hormones such as GLP-1 and GIP. These incretins are vital for maintaining blood sugar balance. By prolonging incretin activity, trelagliptin:\nStimulates insulin secretion from the pancreas\nReduces glucagon release from alpha cells\nHelps lower blood sugar, particularly after meals\nThis mechanism provides both effective glycemic control and improved patient compliance.\nDirections for Use\nTake one tablet of TRELAQWK 50 once a week, on the same day each week\nCan be taken with or without food\nSwallow whole with a glass of water\nFollow your doctor’s advice for dosage adjustment\nDo not double the dose if missed; consult your healthcare provider\nPossible Side Effects\nTRELAQWK 50 is usually well-tolerated. However, some patients may experience:\nMild headache\nNasopharyngitis (cold-like symptoms)\nDiarrhea\nStomach discomfort or indigestion\nRare allergic reactions (rash, itching)\nIf any unusual or persistent side effects occur, seek medical advice promptly.", "price": 375.0, "discountamount": 112.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2165, "imageuri": "https://productimages.withfloats.com/actual/68b023971624ba892ffd8c69.png", "tileimageuri": "https://productimages.withfloats.com/tile/68b023971624ba892ffd8c69.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-08-28T09:38:27.036Z", "updatedon": "2025-08-28T09:38:27.036Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/trelaqwk-50/2165", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "trelagliptin 50 mg", "category": "DIABETIC RANGE", "tags": [], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false } ], "hasmoreitems": false, "isapirequest": false, "totalresults": 27, "query": null, "floatingpoint": null }